A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia

非布索坦 黄嘌呤氧化酶抑制剂 高尿酸血症 药理学 黄嘌呤氧化酶 最大值 药代动力学 尿酸 化学 医学 内科学 生物化学 酶
作者
Chenjing Wang,Qing Yu,Xin Jiang,Yujie Deng,Feifei Sun,Xin Li,Ye Tao,Pingping Lin,Yaping Ma,Yuxian Zhu,Chengqian Li,Yu Cao
出处
期刊:The Journal of Clinical Pharmacology [Wiley]
卷期号:63 (2): 239-249 被引量:6
标识
DOI:10.1002/jcph.2159
摘要

Abstract SHR4640 is a novel, selective urate reabsorption inhibitor. As the mode of action of SHR4640 differs from that of a xanthine oxidase inhibitor, such as febuxostat, coadministration of these drugs may be a treatment option for patients with primary hyperuricemia. We assessed the potential drug–drug interaction between SHR4640 and febuxostat. In this single‐center, open‐label, randomized, drug–drug interaction study, subjects received 80 mg febuxostat or 10 mg SHR4640 alone daily in the first week, whereas during the second week a combination of SHR4640 and febuxostat was administered daily to all subjects. Plasma concentrations of SHR4640 and febuxostat were analyzed. We compared their pharmacokinetic and pharmacodynamic parameters and assessed both safety and tolerability. Compared with febuxostat alone, the geometric mean ratios (90%CIs) of the maximum concentration (C max ) and the area under the plasma concentration–time curve over the dosing interval τ (AUC 0–τ ) for febuxostat after coadministration were 1.284 (1.016 to 1.621) and 0.984 (0.876 to 1.106), respectively. The geometric mean ratios (90%CIs) of C max and AUC 0–τ for SHR4640 after coadministration compared with SHR4640 alone were 0.910 (0.839 to 0.988) and 0.929 (0.893 to 0.966), respectively. Febuxostat had no effect on SHR4640 pharmacokinetic parameters, as the 90%CIs of the geometric mean ratios were all within the range of 0.80 to 1.25. The coadministration of febuxostat and SHR4640 was well tolerated. The coadministration of SHR4640 with febuxostat was not associated with any clinically relevant pharmacokinetic drug interactions. SHR4640 combined with febuxostat had a synergistic effect on reducing uric acid in the pharmacodynamics, with the AUC decreasing from 7440 to 3170 h μmol/L compared with febuxostat alone and from 5730 to 2960 h μmol/L compared with SHR4640 alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiaoyeken发布了新的文献求助10
1秒前
h11发布了新的文献求助10
1秒前
ilc发布了新的文献求助10
1秒前
Venus发布了新的文献求助10
2秒前
xixi发布了新的文献求助10
2秒前
星辰大海的应助被瘦瘦的老三采纳,获得10
2秒前
热情河马发布了新的文献求助10
3秒前
liuapple完成签到,获得积分10
3秒前
null的应助被超级尔白采纳,获得10
3秒前
4秒前
研友_VZG7GZ的应助被无敌的ybk采纳,获得30
4秒前
zzkkzz完成签到,获得积分10
4秒前
4秒前
4秒前
5秒前
5秒前
简单春天发布了新的文献求助10
5秒前
5秒前
6秒前
6秒前
6秒前
直率的电灯胆的应助被嘟噜采纳,获得10
7秒前
8秒前
ZHANGLI完成签到 ,获得积分10
8秒前
xiaoyeken完成签到,获得积分10
8秒前
搜集达人的应助被Kannan采纳,获得10
8秒前
梦安完成签到 ,获得积分10
8秒前
风吹麦浪的应助被瘦瘦的老三采纳,获得10
9秒前
9秒前
熙可檬发布了新的文献求助10
9秒前
9秒前
颜颜发布了新的文献求助10
10秒前
gao456789发布了新的文献求助10
10秒前
10秒前
Zxs完成签到,获得积分20
11秒前
iaii发布了新的文献求助10
11秒前
11秒前
11秒前
经竺的应助被dde采纳,获得10
11秒前
04d的应助被dde采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164555
求助须知:如何正确求助?哪些是违规求助? 9558341
关于积分的说明 21745170
捐赠科研通 7755092
什么是DOI,文献DOI怎么找? 3428591
关于科研通互助平台的介绍 2553128
邀请新用户注册赠送积分活动 2473151